Cytokine Production and Immune Cell Activation in Melanoma Patients Treated with Liposomal Muramyl Tripeptide (CGP 19835A Lipid)1
- 1 January 1993
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Cancer Biotherapy
- Vol. 8 (4), 307-318
- https://doi.org/10.1089/cbr.1993.8.307
Abstract
We conducted a pilot study using liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) preoperatively in patients with stage III or IV resectable melanoma who were at high risk for recurrence. Patients received L-MTP-PE for 1 month before surgery and then 5 months postoperatively. Several immune parameters were monitored during preoperative therapy to search for correlations with clinical (tumor) response. The 18 patients were classified into three groups according to their responses and disease-free intervals: no evidence of disease (NED) at week 24 of therapy, relapse during therapy and progressive disease on therapy noted at the time of surgery. Six of nine patients in the NED group demonstrated increased monocyte tumoricidal activity (MTA) during week 1 of therapy. MTA increased in three of the six patients in the relapse group. MTA did not increase in the three patients who had progressive disease on therapy. Plasma neopterin levels were elevated by 72 h following the first L-MTP-PE dose in all 18 patients. Circulating levels of tumor necrosis factor were elevated in 15 of 16 patients tested, and IL-6 levels were elevated in all 18 patients. Melanoma cells from all three patients with progressive disease at the time of surgery proliferated well in vitro, whereas tumor cells from 10 of the 15 patients in the other two groups did not proliferate. There were no discernible differences among the three groups in the magnitude of IL-2-induced proliferation of tumor infiltrating lymphocytes. However, IL-2-activated TILs from the NED group exhibited cytotoxicity against autologous tumor cells in vitro. In summary, whereas L-MTP-PE stimulated several immunologic responses in all patients, the only two parameters that correlated with clinical status were MTA and the tumor proliferation assay. These two biologic assays could serve to distinguish potential responders from nonresponders early in the course of treatment.Keywords
This publication has 9 references indexed in Scilit:
- Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid)Cancer Immunology, Immunotherapy, 1992
- Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapyCancer Immunology, Immunotherapy, 1991
- Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skinCA: A Cancer Journal for Clinicians, 1991
- Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.Journal of Clinical Oncology, 1991
- Synergistic Antitumor Activity of Etoposide and Human Interleukin-1 Against Human Melanoma CellsJNCI Journal of the National Cancer Institute, 1989
- Tumor Necrosis Factor Enhances the in Vitro and in Vivo Efficacy of Chemotherapeutic Drugs Targeted at DNA Topoisomerase II in the Treatment of Murine Bladder CancerJournal of Urology, 1987
- Prognosis of Patients with Pathologic Stage II Cutaneous Malignant MelanomaAnnals of Surgery, 1985
- A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous MelanomaNew England Journal of Medicine, 1982
- Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic diseaseSpringer Seminars in Immunopathology, 1982